| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $12.8M | -45.0% | +38.5% |
| R&D Expense | $36.7M | +19.7% | +32.8% |
| SG&A Expense | $9.1M | +12.0% | +11.5% |
| Operating Income | -$33.0M | -112.0% | -24.3% |
| Pre-tax Income | -$30.3M | -172.7% | -27.2% |
| Income Tax | -$3.2M | -365.0% | -4574.6% |
| Net Income | -$27.1M |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $208.3M | +200.1% | +65.9% |
| Current Assets | $401.8M | +34.2% | +60.0% |
| Total Assets | $459.8M | +27.9% | +45.9% |
| Current Liabilities | $61.4M | +46.8% | +47.6% |
| Total Liabilities | $214.0M | +133.9% | +95.2% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | $20.2M | — | — |
| Capital Expenditures | $3.9M | — | — |
| Investing Cash Flow | -$36.8M | — | — |
| Financing Cash Flow | $727K | — | — |
| Free Cash Flow | $16.3M | — | — |
| -120.3% |
| -13.5% |
| $245.8M |
| -8.3% |
| +19.7% |